Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

Summary

Market analysis report highlights strong expected growth in the inflammatory bowel disease market from 2026-2036, driven by emerging therapies including ABX464 from Abivax targeting IL-23, TL1A, and S1P pathways. The growth is attributed to rising prevalence, increased disease awareness, and earlier diagnosis of Crohn's disease and ulcerative colitis.